The present invention provides, in its principal aspect, compounds of the general formula:
where
A is —NHCO—, —N(CH3)—CO—, —NHCH2—, —N(CH3)—CH2—, —COCH2—, —CH2CH2—, or —CH(OH)CH2—,
X is H, CH3, NH2, NH(CH3), N(CH3)2, OCH3, or SH;
R2 is hydrogen or a methyl or ethyl group;
R3 is hydrogen or a methyl or ehtyl group;
n is 0, 1, 2, 3, 4, 5 or 6;
R1 is selected from the group consisting of (a) alkyl; (b) C3 to C8 cycloalkyl; (c) phenyl or substituted phenyl; (d) heterocyclic; (e) decahydronaphthalene and (f) octahydroindane; or R1 and X may be taken together to denote a 5,6 or 6,6 saturated bicycle ring structure.
The compounds of the present invention have H3 histamine receptor antagonist activity. This invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of formula 1.0. The present invention also provides a method of treating conditions in which antagonism of histamine H3 receptors may of therapeutic importance.
本发明主要提供一般式化合物,其中A为—NHCO—、—N(
CH3)—CO—、—NH —、—N( )—
CH2—、—CO —、— —或—CH(OH) —,X为H、 、NH2、NH( )、N( )2、O 或SH;R2为氢或甲基或乙基基团;R3为氢或甲基或乙基基团;n为0、1、2、3、4、5或6;R1选自以下组成的群体:(a)烷基;(b)C3到C8环烷基;(c)苯基或取代苯基;(d)杂环;(e)十氢
萘或(f)八氢
萘;或R1和X可以一起表示为一个5,6或6,6饱和双环环状结构。本发明化合物具有H3
组胺受体拮抗活性。本发明还提供了包括药用载体和一定量的1.0式化合物的药物组合物。本发明还提供了一种治疗
组胺H3受体拮抗剂可能具有治疗重要性的疾病的方法。